Lecigon is an advanced therapy that incorporates the triple combination of levodopa, carbidopa and entacapone, a novel intestinal gel dosing pump technology to improve the quality of life for Parkinson’s patients. According to data from the Spanish Society of Neurology, nearly 120,000 people suffer from this neurodegenerative disease in our country.
It is already available in our country lecigona new therapy for advanced Parkinson’s disease arrives in our country, whose rights were acquired by STADA in October 2020 and has already been successfully launched in 20 countries such as Germany, Austria, Belgium and the Netherlands. Now it arrives in Spain, where the first patients are already receiving this treatment.
This treatment provides benefits in terms of bioavailability and quality of life for the patient by incorporating the triple combination of levodopa, carbidopa and entacaponein a Innovative intestinal gel dosing pump technology.
Lecigon is based on a novel intestinal gel dosing pump technology
As pointed out mar fabregasCEO of STADA Spain, “with Lecigon we are taking our purpose of caring for people’s health one step further to treat advanced Parkinson’s disease”. Currently, according to data from the Spanish Society of Neurology (), nearly 120,000 people In our country have Parkinson’sdiagnosing 10,000 new cases each year.
What is Lecigon?
Lecigon is used in the treatment of this pathology, with severe motor fluctuations and hyperkinesia or dyskinesiawhen the available oral combinations do not produce satisfactory treatment results.
The new drug is a infusion administered into the small intestine of the patient by means of a dosing pump, discreet, light and portable. This pump has a intuitive and easy to use interface, with a long-lasting battery. In addition, healthcare personnel can schedule multiple dosesto adapt to the different needs of the patient.
The gel formulation of the three active ingredients widely used for Parkinson’s, has a positive effect on bioavailability of levodopa. In addition, the dosing pump can be removed and the patient can even bathe, shower or perform other physical activities, if his general condition allows it. This situation makes the patient have greater flexibility and can plan their daily life.
“In this way, STADA demonstrates that it not only brings value and accessibility in the area of generic drugs and consumer health, but also in our fast-growing specialty drugs segment. We are very pleased to be able to offer this novel product that contributes significantly to the care of patients with Parkinson’s“adds the general director of .
This pharmacist offers a comprehensive package of support services for patients and caregivers during treatment, for the release of Lecigon. Also, there is a 24-hour phone line hours for questions related to the dosing pump, and a complete package of materials that provides additional support for patients and physicians.